Navigation Links
Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
Date:7/29/2010

w a personalized approach to patient treatment by making it possible for the first time, to select a clinical dose capable of saturating 5-HT2A receptors while permitting the "dialing in" of an optimal amount of dopamine receptor modulation by simple dose adjustments using a single drug.  At low doses, ITI-007 improves sleep in patients suffering from insomnia characterized by difficulty maintaining sleep throughout the night, without producing daytime sedation.  In contrast to most other antipsychotic medications, ITI-007 is non-sedating, increasing sleep and decreasing wakefulness during the night with no daytime drowsiness or next-day hangover effects.  At higher doses, the ability to optimize the level of dopamine receptor modulation holds promise for the reduction of acute as well as chronic psychotic symptoms in patients with schizophrenia without incurring motor disturbances and other deleterious side effects. Importantly, ITI-007 also has a low propensity, much lower than currently marketed antipsychotic drugs, to bind receptors that mediate deleterious cardiovascular events, profound sedation and rapid and significant weight gain. In addition, the wide separation of affinity at 5-HT2A and D2 receptors may allow for administration of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy and the treatment of bipolar disorder, posttraumatic stress disorder, behavioral disturbances in Alzheimer's disease, and autism. The serotonin reuptake inhibition allows for additional antidepressant efficacy for the treatment of schizoaffective disorder, co-morbid depression, and/or as a stand-alone treatment for major depressive disorder (MDD).

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS).  Building
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
2. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
3. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
5. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
6. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
7. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
8. Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity
9. Reportlinker Adds Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
10. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
11. Drug in New Class of Targeted Therapies Shows Early Promise Against Blood-Related Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Feb. 24, 2011 GlaxoSmithKline (GSK), one of ... 2010 Environmental Stewardship Award from Nalco Company (NYSE: ... ongoing efforts to reduce its climate change impact ... http://photos.prnewswire.com/prnh/20101231/NALCOLOGO ) The Environmental Stewardship ...
... N.C., Feb. 24, 2011 Chimerix, Inc., a pharmaceutical ... announced today that Kenneth I. Moch, President and Chief ... Health Care Conference on March 1, 2011 at 3:00 ... New York City, NY. Mr. Moch will ...
Cached Medicine Technology:GlaxoSmithKline Wins Environmental Stewardship Award 2GlaxoSmithKline Wins Environmental Stewardship Award 3Chimerix to Present at the Citi 2011 Global Health Care Conference 2Chimerix to Present at the Citi 2011 Global Health Care Conference 3
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... Calif., Oct. 10 AlphaDetail, Inc., a leader,in primary ... Life Sciences Industry, continues to affirm its commitment to ... on the east coast. AlphaDetail will open a ... This will benefit a large number of clients located ...
... Oct. 10 The Pennsylvania,Department of Health today ... (CDC) advisory for consumers not to eat Banquet ... due to possible,Salmonella contamination., "Federal officials have ... want to ensure Pennsylvanians are taking the,appropriate measures ...
... Inc. (OTC,Bulletin Board: SCIE) announced today that it ... Company,s quality system from the Notified,Body G-MED. SpectraScience ... II.3 of the European directive 93/42/EEC. In addition, ... Jim Hitchin the Company,s CEO said, "This certification ...
... 10 Good Shepherd,Rehabilitation Network has expanded ... The virtual store at, http://www.rehabilitystores.com with ... of secure online shopping specifically for those ... and their caregivers., "Rehability offers a ...
... Rural/Metro,Corporation announced that a majority of its ... Capital Management LLC, the Company,s,largest stockholder. During the ... and constructive dialogue. The Board,s desire is to ... remains committed,to doing what is best to enhance ...
... likely to develop breathing problems, study finds, , , WEDNESDAY, Oct. ... in their first month of life were more likely to ... a new study found. , Danish researchers found that infants ... influenzae or Moraxella catarrhalis bacteria had more ...
Cached Medicine News:Health News:AlphaDetail, Inc. Affirms Commitment to Local East Coast Presence 2Health News:Salmonella Outbreak Traced to Banquet and Store Brand Frozen Pot Pies 2Health News:SpectraScience Receives Final European Certification 2Health News:Those With Disabilities as Well as Aging Population Throughout Country Now Have Access to Thousands of Specialized Products 2Health News:Rural/Metro Board of Directors Meets With Accipiter Capital Management 2Health News:Rural/Metro Board of Directors Meets With Accipiter Capital Management 3Health News:Early Bacterial Infection May Boost Asthma Risk 2Health News:Early Bacterial Infection May Boost Asthma Risk 3
... Affinity pacemaker family offers ... truly automatic devices. Featuring ... of advanced technologies ever ... pacemaker incorporates the exclusive ...
Medtronic, Inc., a world leader in therapies for restoring people with chronic conditions to full life, introduces the AT500 Pacing System for the management of atrial tachyarrhythmias and bradycardi...
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety....
... Powerful, flexible, and fast, the ... combines leading edge technologies with user-oriented ... The integrated SONO MR package consists ... and control, including HI COMPOUND multi-angle ...
Medicine Products: